2.8
Mutagenicità e cancerogenicità
La mutagenicità e la cancerogenicità si riferiscono rispettivamente alla capacità dei farmaci di causare difetti genetici e di indurre il cancro. L'Ag…
La modifica del DNA indotta da farmaci è chiamata mutagenicità. Se le mutazioni colpiscono i geni oncosoppressori o i proto-oncogeni, può portare alla cancerogenesi.
La cancerogenesi inizia con l'inizio del tumore. Qui, un cancerogeno genotossico, chiamato iniziatore, muta un gene per inibire l'apoptosi cellulare e promuovere la proliferazione.
Segue la fase di promozione del tumore, in cui un cancerogeno epigenetico, chiamato promotore, altera l'ambiente cellulare per promuovere la sopravvivenza delle cellule precancerose.
La IARC classifica le sostanze chimiche in quattro gruppi in base al loro potenziale cancerogeno.
Il potenziale genotossico di tali agenti cancerogeni è valutato utilizzando test in vitro e in vivo.
I test di mutagenicità in vitro come il test di Ames, le aberrazioni cromosomiche e i saggi di scambio di cromatidi fratelli sono rapidi e poco costosi, ma possono avere alcuni risultati falsi.
I test di cancerogenicità in vivo prevedono la somministrazione cronica negli animali, seguita dall'individuazione di tumori. Sebbene siano costosi e dispendiosi in termini di tempo, sono necessari per valutare i rischi per la salute umana.
View the full transcript and gain access to JoVE Core videos
Q1: What is the difference between mutagenicity and carcinogenicity?
Mutagenicity refers to drug-induced modification of DNA, while carcinogenicity is the ability to induce cancer. Mutations affecting tumor suppressor genes or proto-oncogenes can lead to carcinogenesis. Not all mutations cause cancer, but those affecting genes regulating cell growth may result in cancer development through effects of chemicals overview.
Q2: How does carcinogenesis progress through tumor initiation and promotion?
Tumor initiation occurs when a genotoxic carcinogen called an initiator mutates a gene to inhibit cellular apoptosis and promote proliferation. Tumor promotion follows, where an epigenetic carcinogen called a promoter alters the cellular environment to promote survival of pre-cancerous cells, advancing cancer development.
Q3: How does the IARC classify carcinogenic chemicals?
The IARC categorizes chemicals into four groups based on carcinogenic potential. Group 1 includes known human carcinogens; Group 2A contains probably carcinogenic agents; Group 3 lacks sufficient data; and Group 4 includes agents with data supporting they are not likely carcinogens.
Q4: What are the advantages and limitations of in vitro mutagenicity tests?
In vitro tests like the Ames test, chromosome aberrations, and sister chromatid exchange assays are rapid and inexpensive screening tools. However, they have limited predictive value for carcinogenicity and can produce false results, requiring confirmation with more comprehensive in vivo testing.
Q5: Why are in vivo carcinogenicity tests necessary despite their drawbacks?
In vivo carcinogenicity tests involve chronic animal dosing followed by tumor detection. Although expensive and time-consuming, they are required to assess risks to human health and are mandated by regulatory authorities before licensing drugs for clinical use. These tests provide essential safety data.
Q6: How can reactive metabolites contribute to mutagenicity and carcinogenicity?
Reactive metabolites formed during drug oxidation can cause structural chromosomal abnormalities and DNA mutations. These metabolites may also modify cellular signaling pathways and the cellular environment, promoting survival and proliferation of pre-cancerous cells through non-DNA interactions and toxic reactions overview.
Q7: What substances are known to have mutagenic and carcinogenic potential?
Substances with mutagenic and carcinogenic potential include anticancer drugs, estrogens, tobacco, and radioisotopes. These agents can cause genetic defects and induce cancer through various mechanisms, making their assessment critical for drug safety, public health protection, and regulatory compliance in clinical practice.